Pembrolizumab in Advanced Gastric Cancer Treatment
Kei Muro, MD, discusses phase II and III trials which examine pembrolizumab as a treatment for patients with advanced gastric cancer.
Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses phase II and III trials examining pembrolizumab as a treatment option for patients with advanced gastric cancer.
Clinical Pearls:
- A phase II trial examining pembrolizumab and chemotherapy in this space is said to start in the first quarter of 2015. Previous data show that pembrolizumab is a promising antitumor activity with manageable toxicity in patients with advanced gastric cancer (GC).
- The trial will include three cohorts examining pembrolizumab alone in previously treated patients, a combination of pembrolizumab with cisplatin and 5-fluorouracil in eligible patients, and pembrolizumab alone in treatment naive patients.
- Two upcoming phase III trials will examine pembrolizumab versus weekly paclitaxel as a second-line treatment for patients with GC, and a pembrolizumab as a​ first-line treatment for patients with advanced GC.
Articles in this issue
Expert Investigators Discuss Emerging Therapies for GI Cancers
Predictors of Toxicity in Colon Cancer Treatment Identified
Many Biliary Tract Cancers Harbor Actionable Mutations
KRAS Mutant ctDNA Assay Performance Comparable in Urine and Plasma for Advanced CRC
Safety of Regorafenib Confirmed in Patients With mCRC and High PFS
Chemotherapy Treatment in Gastric Cancer
Pembrolizumab in Advanced Gastric Cancer Treatment
Onartuzumab for Gastroesophageal Adenocarcinoma
FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer
Recent Videos
Related Content
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Article
Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
